Scarica l'app Stockscreener
13.62
7.03%
-1.03
Dopo l'orario di chiusura:
13.62
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Precedente Chiudi:
$14.65
Aprire:
$15.15
Volume 24 ore:
5.34M
Relative Volume:
0.97
Capitalizzazione di mercato:
$4.22B
Reddito:
-
Utile/perdita netta:
$-127.69M
Rapporto P/E:
-30.21
EPS:
-0.4508
Flusso di cassa netto:
$-98.43M
1 W Prestazione:
-11.96%
1M Prestazione:
+13.50%
6M Prestazione:
+773.08%
1 anno Prestazione:
+826.53%
Intervallo 1D:
$13.54
$15.56
Intervallo di 1 settimana:
$13.54
$16.41
Portata 52W:
$1.01
$16.41
Erasca Inc Stock (ERAS) Company Profile
Nome
Erasca Inc
Settore
Industria
Telefono
(858) 465-6511
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
13.62 | 4.22B | 0 | -127.69M | -98.43M | -0.4508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Ripresa | Mizuho | Outperform |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-10-16 | Iniziato | Stifel | Buy |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Iniziato | Raymond James | Outperform |
| 2024-11-18 | Iniziato | Jefferies | Buy |
| 2024-03-11 | Iniziato | CapitalOne | Overweight |
| 2024-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-03-30 | Iniziato | Mizuho | Buy |
| 2023-02-24 | Iniziato | Goldman | Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Erasca Inc Borsa (ERAS) Ultime notizie
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 By Investing.com - Investing.com Nigeria
Erasca’s Chief Medical Officer Divests Shares Amid Strategic Uncertainties - StocksToTrade
Erasca stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com Nigeria
Stifel reiterates Buy rating on Erasca stock, $20 target - Investing.com
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Decoding Erasca Inc (ERAS): A Strategic SWOT Insight - GuruFocus
Erasca, Inc. 2025 Annual Report: Erasing Cancer with Modality-Agnostic RAS/MAPK Pathway Therapeutics and Innovative Precision Oncology Strategies - Minichart
Erasca 10-K: Net loss $124.55M; cash and securities $341.8M - TradingView
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results - Bitget
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015 - simplywall.st
Erasca (ERAS) to Release Earnings on Thursday - MarketBeat
Stifel raises Erasca stock price target to $20 on China expansion - Investing.com
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau - Bitget
Global cancer drug rights: Erasca takes ERAS-0015 worldwide - Stock Titan
Erasca Inc stock hits 52-week high at $14.63 - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Hits New 52-Week HighTime to Buy? - MarketBeat
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - 24/7 Wall St.
Erasca (ERAS) And Tango Target MTAP-Deleted Cancers With Dual Inhibition Strategy – What Changes? - simplywall.st
Growth Recap: How interest rate cuts could boost Erasca Inc. stock2025 Technical Overview & Community Verified Watchlist Alerts - Naître et grandir
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - The Globe and Mail
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com
Erasca Insider Sold Shares Worth $300,760, According to a Recent SEC Filing - marketscreener.com
Erasca’s chief medical officer Morris sells $300k in ERAS stock - Investing.com
Erasca (ERAS) Sees Target Price Raised By Clear Street To $20 | - GuruFocus
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Sahm
Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Investment Magazine
Clear Street raises Erasca stock price target on combination trial deal - Investing.com Australia
Clear Street raises Erasca stock price target on combination trial deal By Investing.com - Investing.com South Africa
Erasca and Tango Therapeutics Partner to Study ERAS-007 and Vopimetostat Combination for MTAP-Deleted Cancers - geneonline.com
Assessing Tango Therapeutics (TNGX) Valuation After Earnings Update And New Erasca Trial Collaboration - simplywall.st
Tango rises after Q4 results, clinical pact with Erasca - Seeking Alpha
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat - Bitget
Biopharmaceutical company Erasca, Inc. (NASDAQ: ERAS) and Tango Therapeutics Inc. (NASDAQ: TNGX) announced a clinical collaboration to jointly conduct clinical evaluation of the combination therapy of ERAS-0015 and vopimetostat. - Bitget
Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy - marketscreener.com
Erasca and Tango Therapeutics enter into clinical collaboration to evaluate combination of ERAS-0015 and vopimetostat - marketscreener.com
Erasca, Tango test dual-drug attack on tough pancreatic, lung cancers - Stock Titan
Erasca Inc stock hits 52-week high at $14.63 By Investing.com - Investing.com Canada
Erasca stock reaches 52-week high at 12.48 USD - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Hits New 1-Year HighShould You Buy? - MarketBeat
Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Erasca, Inc. (ERAS): A Bull Case Theory - Insider Monkey
Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 - Yahoo Finance
ERAS: Lead RAS-targeted therapies show strong early data, with major trial updates expected in 2024 - TradingView
ERAS: Lead RAS-targeted therapies show promising early results, with key clinical updates expected in 2024 - TradingView
Erasca, Inc. (ERAS) Stock Analysis: Unlocking Potential in Precision Oncology with a Robust Pipeline - DirectorsTalk Interviews
Erasca Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Erasca stock hits 52-week high at $13.30 By Investing.com - Investing.com India
Assessing Erasca (ERAS) Valuation After New Pan KRAS Patent Win Through 2043 - simplywall.st
Erasca (NASDAQ:ERAS) Hits New 12-Month HighHere's What Happened - MarketBeat
Erasca stock hits 52-week high at $13.30 - Investing.com
Erasca Inc Azioni (ERAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):